Liquid biopsy solutions for sensitive circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) detection in precision oncology research.
Liquid biopsy samples allow for non-invasive and repeatable monitoring of tumor evolution and are increasingly being relied upon for clinical trials.
At CellCarta, our liquid biopsy platforms can extract key information from your samples to support biomarker discovery, patient stratification, and clinical trial management.
Our liquid biopsy workflows are validated to the highest standards and are conducted in a GCLP and CAP/CLIA-accredited environment.
Uncover key cellular insights using our various liquid biology platforms, including:
Depending on your research context, sample type, and clinical endpoints, our team of experts can tailor which platforms are relevant to your study, ensuring quality data, not just quantity.
Our workflows can support key off-the-shelf (OTS) assays to uncover in-depth information regarding your samples, including:
Customized panels can also be developed to support your sample type and targets of interest, with validation services in-place to meet your study at any stage. Contact our team to learn more.
Receive access to our in-house biobank, a database that is fully searchable by phenotype, biomaterial type, and disease indicators.
Our global network of laboratories provides high-quality PBMC processing and sample management services to ensures proper handling, transport, and storage of samples while in our care, supporting data integrity and streamlining clinical trial progression.
Uncover key cellular insights using our various liquid biology platforms, including:
Depending on your research context, sample type, and clinical endpoints, our team of experts can tailor which platforms are relevant to your study, ensuring quality data, not just quantity.
Our workflows can support key off-the-shelf (OTS) assays to uncover in-depth information regarding your samples, including:
Customized panels can also be developed to support your sample type and targets of interest, with validation services in-place to meet your study at any stage. Contact our team to learn more.
Receive access to our in-house biobank, a database that is fully searchable by phenotype, biomaterial type, and disease indicators.
Our global network of laboratories provides high-quality PBMC processing and sample management services to ensures proper handling, transport, and storage of samples while in our care, supporting data integrity and streamlining clinical trial progression.
For tissue and liquid biopsies, CellCarta can perform the TSO500 assay, a cutting-edge next-generation sequencing (NGS) tool for rapid and high-throughput sample processing from a small starting volume. This makes TSO500 a valuable tool for biomarker discovery, immune responses, and clinical trials.
CellCarta is a qualified service provider for RareCyte®, enabling the analysis of cell-free DNA (cfDNA) and circulating tumor cells (CTCs), cells originating from tumors into the blood, allowing for distant metastasis.
Our RareCyte platform uses the CyteFinder®HT instrument for precise CTC enumeration, phenotypic characterization, and biomarker identification.
A sensitive, accurate, simple, and scalable workflow.
DAPI, CD45, EpCAM, and ≤2 select biomarkers assessed at once.
Expert slide preparation, handling, and processing.
A complete data management pipeline for high-dimensional images.
We validated the Aspyre® Lung assay as a clinical trial assay for patients with non-small cell lung cancer (NSCLC) in accordance with ISO 13485 regulations. Notably, Aspyre enables the accurate, rapid, and sensitive detection of NSCLC variants from minimal sample input, making it the ideal exclusion assay.
Our workflows enable the smooth integration of liquid biopsy samples into your research.
High-End Scientific Capabilities
Non-Invasive Collection
Global Execution
Cutting-Edge Platforms
Adaptable Workflows
Genomics solutions for all phases of drug development and CDx development.
Measure the expression of analytes for biomarker discovery and immune monitoring.
Sensitive and accurate platform for scalable proteomic monitoring and bioanalysis under GCLP and QC conditions.
Your liquid biopsy samples can be used to extract valuable data across all our areas of expertise – proteomics, genomics, histopathology, and immune monitoring. Depending on your sample type and study endpoint, we can tailor which platforms are run, optimizing your data to align best with your study’s specification. These platforms include dPCR, nCounter, next-generation sequencing, histopathology, immunoassays, flow cytometry, and mass spectrometry.
CellCarta is a certified RareCyte provider, enabling robust CTC analysis services from your liquid biopsy samples through mIF-based platforms.
CellCarta is a RareCyte service provider, a robust workflow to simplify cfDNA and CTC analysis from liquid biopsy samples. RareCyte has several advantages, especially for large-scale clinical trials.
Our slide preparation is density-based and eliminates manual wash steps, reducing the risk of cell loss and user error.
Identified CTCs are immunophenotyped using automated IF assays (DAPI, CD45, EpCAM, CK), and up to two additional biomarkers can be assessed for in-depth phenotypic characterization. Our imaging team then uses the CyteFinder platform and integrated ML/AI image analysis software to classify CTCs with ease.
The RareCyte workflow allows CTCs to be physically isolated from the slide for downstream multi-omics characterization.
Our team of experts can run a variety of assays, including TSO500 for comprehensive NGS-based genomic profiling, oncoReveal Essential LBx and oncoReveal Fusion LBx for targeted liquid biopsy variant detection, nCounter, and Aspyre Lung for NSCLC biomarker analysis in blood samples.
For mutation-specific testing, we offer cobas and Qiagen therascreen kits targeting clinically relevant genes including EGFR, KRAS, BRAF, PIK3CA, and FGFR.
Where no off-the-shelf assay fits your endpoints, our scientists can develop and validate custom assays tailored to your study.
The TruSight Oncology 500 (TSO500) panel interrogates 523 cancer-related genes from DNA and 55 from RNA, enabling detection of SNVs, indels, CNVs, and gene fusions from both tissue and liquid biopsy (plasma) samples in a single, consolidated workflow.
By combining multiple biomarker readouts into one NGS assay, TSO500 requires less sample material, shortens turnaround time, and aiding in the identification of actionable genomic alterations. Its automated workflow supports up to 192 samples per run, making it highly scalable for large clinical programs.
